FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
MGC Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for MGC Pharmaceuticals Limited (MGCLF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMGCLF
MGCLF
MGC Pharmaceuticals Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MGCLF
Home🔹Stocks🔹MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited

MGCLF•OTC

MGC Pharmaceuticals Limited

MGCLF•OTC
Market cap
$12.11M
Sentiment

Your view on MGCLF

Mkt Cap
$12.11M
Sentiment
Your view
MGCLF
MGC Pharmaceuticals Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MGCLF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About MGC Pharmaceuticals Limited

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Roby Reuven Zomer
Headquarters
1202 Hay Street, West Perth, WA, AU
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Roby Reuven Zomer
Headquarters
1202 Hay Street, West Perth, WA, AU
Description

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News